![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 27, 2026
Progress in geriatric oncology, reflections on regulatory complexity, and an exciting new trial in small cell lung cancer
February 27, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
February 27, 2026
The latest clinical trial findings in breast cancer, leukemia, lymphoma, lung cancer, NCI-MATCH, and prostate cancer
January 30, 2026
10 cancer research discoveries in 2025 by ECOG-ACRIN and PrECOG that captured attention across the scientific and patient advocacy communities
December 19, 2025
The trials explore potential treatment improvements for different cancer types: bladder, lung, lymphoma, myeloma, and stomach
November 21, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
October 17, 2025
Summaries of two clinical trials presented at the 2025 World Conference on Lung Cancer
September 19, 2025
Timely information about research presented at medical meetings, recognition of research leaders, and more
July 10, 2025
This clinical trial aims to improve survival for high-risk patients by adding a targeted therapy to standard post-surgery immunotherapy
July 10, 2025
The latest clinical trial findings in breast, lung, nose/sinus, and throat cancers, as well as melanoma and cancer survivorship
June 11, 2025
The group is recognizing Dr. Schiller for her sustained commitment to mentoring early- and mid-career investigators in cancer medicine and in ECOG-ACRIN
June 11, 2025
Researchers with the ECOG-ACRIN Cancer Research Group presented a number of research findings at the 2025 ASCO Annual Meeting